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tBarth syndrome (BTHS), a mitochondrial disorder caused by mutation of the gene Tafazzin
(TAZ). Using BTHS iPSC-derived cardiomyocytes (iPSC-CMs), we defined metabolic, structural,
and functional abnormalities associated with TAZ mutation. BTHS iPSC-CMs assembled sparse
and irregular sarcomeres, and engineered BTHS “heart on chip” tissues contracted weakly. Gene
replacement and genome editing demonstrated that TAZ mutation is necessary and sufficient for
these phenotypes. Sarcomere assembly and myocardial contraction abnormalities occurred in the
context of normal whole cell ATP levels. Excess levels of reactive oxygen species mechanistically
linked TAZ mutation to impaired cardiomyocyte function. Our study provides new insights into
the pathogenesis of Barth syndrome, suggests new treatment strategies, and advances iPSC-based
in vitro modeling of cardiomyopathy.
Barth syndrome (BTHS) is an X-linked cardiac and skeletal mitochondrial myopathy caused
by mutation of the gene Tafazzin (TAZ)1, an acyltransferase responsible for normal acylation
of cardiolipin, the major phospholipid of the mitochondrial inner membrane2
(Supplementary Fig. 1). Cardiolipin abnormalities are also seen in ischemic heart disease
and aging and have been implicated in the cardiac dysfunction in these conditions3. The
mechanisms that lead from abnormal cardiolipin biogenesis to cardiomyopathy are not well
understood. Here, we combined patient-derived iPSCs, genome-edited iPSCs, modified
RNA (modRNA)4, and “heart on a chip”5 technologies to replicate the pathophysiology of
Barth syndrome (BTHS) cardiomyopathy in tissue constructs. Using these approaches, we
identified mitochondrial functional abnormalities caused by TAZ mutation and cardiolipin
deficiency. We show that TAZ mutation is necessary and sufficient to disrupt sarcomere
assembly and contractile stress generation, and that these phenotypes are not due to global
ATP depletion. Furthermore, we show that the BTHS cardiomyopathic phenotype is readily
reversed by reintroduction of wild-type TAZ, or by suppression of excessive reactive
oxygen species (ROS) produced by BTHS mitochondria. These results provide new insights
into the links between mitochondrial function, sarcomere assembly, and muscle contractile
activity and suggest new therapeutic strategies for BTHS.
An iPSC-CM model of Barth syndrome
To investigate BTHS pathogenesis in a controlled in vitro setting, we generated iPSCs from
two unrelated individuals with Barth Syndrome. Two lines, BTH-H and BTH-C,
reprogrammed using retroviral6 or modified RNA approaches7,8, respectively, had
confirmed TAZ frameshift (c.517delG) and missense (c.328T>C) mutations, respectively.
These iPSC lines had normal karyotype and met pluripotency criteria (Supplementary Fig. 2;
all cell lines in this study are summarized in Supplementary Table 1). As controls, we used
three normal iPSC lines, generated by retroviral (WT1 and WT2) or modified RNA (WT3)
reprogramming (Supplementary Table 1). The experiments presented below were
reproduced in multiple experiments and multiple cell lines with consistent results; due to
space restrictions we provide representative data in the accompanying figures and
supplementary data and refer the reader to Supplementary Table 2 for an overview of the
data collected.
We differentiated the iPSCs into iPSC-CMs using an established protocol9 (Supplementary
Fig. 3a–c), followed by magnetic cell sorting for the cardiomyocyte surface marker
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tVCAM110,11 to yield preparations containing ~80% cardiomyocytes (Supplementary Fig.
3d–f). On replating, the enriched myocytes formed sheets of cardiomyocytes
(Supplementary Fig. 3g) that beat spontaneously (Supplementary Movie 1).
BTHS is characterized by depletion of mature cardiolipin and accumulation of an immature
form, monolysocardiolipin (Supplementary Fig. 1).12,13 Phospholipid profiles of BTHS
iPSC-CMs, measured by mass spectrometry, confirmed that BTHS iPSC-CMs replicated
abnormal cardiolipin processing (Fig. 1a). The monolysocardiolipin to cardiolipin ratio in
BTHS iPSC-CMs exceeded 0.3, the clinically used diagnostic threshold for BTHS13 (Fig.
1a, b). Thus, BTHS iPSC-CMs exhibited impaired cardiolipin biogenesis that matched what
is observed clinically in BTHS patients.
We assessed mitochondrial form and function in BTHS iPSC-CMs. By FACS analysis,
BTHS iPSC-CMs had similar mitochondrial number compared control iPSC-CMs, and the
size of BTHS iPSC-CM mitochondria was less than controls (Supplementary Fig. 4a,b).
This corresponded to greater mitochondrial fragmentation of BTHS iPSC-CM mitochondria
compared to the more highly networked mitochondria of controls (Fig. 4c). To assess BTHS
mitochondrial function, we cultured iPSC-CMs in galactose-based media, which has limited
ability to support ATP production via glycolysis.14 Under these conditions, BTHS iPSC-CM
ATP levels were significantly lower than controls (Fig. 1c). Consistent with cellular energy
deprivation, AMP-dependent kinase (AMPK) was markedly activated in BTHS iPSC-CMs
(Supplementary Fig. 5a). Next, we used an extracellular flux analyzer to probe
mitochondrial function (approach and terms summarized in Supplementary Fig. 5b,c).
BTHS iPSC-CMs unexpectedly exhibited elevated basal oxygen consumption rate, which
was due to both increased F1F0 ATP synthase oxygen consumption and increased “H+ leak”
(Fig. 1d, e and Supplementary Fig. 5d). In the context of reduced basal ATP levels, these
data pointed to inefficient F1F0 ATP synthase activity, which we confirmed by selective
complex immunocapture followed by measurement of its quantity and activity
(Supplementary Fig. 5e). Collectively, the data demonstrate that TAZ deficiency and
consequent cardiolipin abnormalities reduce peak electron transport chain function and
decrease ATP generating efficiency by lowering F1F0 ATP synthase specific activity.
We also measured maximal electron transport chain activity (“Respiratory Capacity”) and
found that it was severely impaired in BTHS iPSC-CMs (Fig. 1d, e). The metabolic
abnormalities of BTHS iPSC-CMs were not evident in BTHS primary fibroblasts or iPSCs
(Supplementary Fig. 5f, g), consistent with the muscle-selective phenotype of BTHS
patients.
Cardiomyocytes are capable of producing ATP through both glycolysis and oxidative
phosphorylation. We hypothesized that glucose, an energy source that supports both
glycolysis and oxidative phosphorylation, would normalize ATP levels. Indeed glucose
induced glycolysis and triggered a metabolic shift away from oxidative phosphorylation in
both BTHS and control iPSC-CMs (Supplementary Fig. 5h,i). This metabolic shift
normalized BTHS iPSC-CM ATP levels and basal oxygen consumption rate (Fig. 1f and
Supplementary Fig. 5j). However, glucose culture did not correct the markedly depressed
respiratory capacity of BTHS iPSC-CMs (Supplementary Fig. 5j). These observations
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tindicate that glucose restores basal ATP levels through increased glycolysis, but does not
correct underlying mitochondrial defects in the electron transport chain.
TAZ mutation causes BTHS iPSC-CM phenotypes
Because BTHS patient-derived and control iPSCs had numerous genetic differences other
than TAZ mutation, we took three independent approaches to further establish the causative
role of TAZ mutation in abnormal cardiolipin biogenesis and mitochondria function. First,
we used adenoviral delivery of TAZ-specific short hairpin RNAs (shRNAs) to deplete TAZ
in neonatal rat ventricular cardiomyocytes (NRVMs) by over 80% by 72 hours post-
infection (Supplementary Fig. 6a). By this time point, cardiolipin profiles in TAZ
knockdown NRVMs were already highly abnormal (Supplementary Fig. 6b), indicating
rapid turnover of TAZ and mature cardiolipin. As in the BTHS iPSC-CMs, TAZ deficiency
in NRVMs grown in galactose reduced ATP levels, activated AMPK (Supplementary Fig.
6c, d), and caused comparable abnormalities in mitochondrial function (Supplementary Fig.
6e). Electron microscopy did not reveal alterations in mitochondrial morphology or number
in this short term TAZ depletion experiment (Supplementary Fig. 6f), suggesting that
mitochondrial functional abnormalities are not contingent upon mitochondrial structural
abnormalities observed in BTHS patients.
Second, we used a novel method to efficiently re-introduce TAZ into BTHS iPSC-CMs.
Cardiomyocytes, including iPSC-CMs, are refractory to standard transfection methods. We
synthesized TAZ mRNA, substituting 5-methylcytidine for cytidine, and pseudouridine for
uridine4,7,15. This modified RNA (“modRNA”) has minimal toxicity4,7,15 and efficiently
transfects cardiomyocytes (Supplementary Fig. 7). TAZ modRNA likewise transfected
iPSC-CMs, and TAZ protein localized to mitochondria (Fig. 2a). TAZ modRNA restored
cardiolipin biogenesis and normalized basal mitochondrial function in BTHS iPSC-CMs,
although maximal respiratory capacity was rescued incompletely (Fig. 2b–e). These results
indicate that TAZ mutation is necessary for the BTHS mitochondrial phenotype, and that
this phenotype is rapidly reversed upon TAZ restoration.
Third, we used Cas9-mediated scarless genome editing16 to mutate TAZ in the control
human line PGP1-iPSC, yielding three iPSC lines that are isogenic except for the sequence
of TAZ exon 6 (Supplementary Table 1 and Fig. 3a–c; see Methods and Supplementary Fig.
8 for details on construction and validation of these iPSC lines). PGP1-TAZc.517delG
contains the TAZ frameshift mutation from the BTH-H line (1 nt deletion), while PGP1-
TAZc.517ins contains a distinct frameshift mutation at the same site (14 nt insertion; Fig. 3a–
c). PGP1-TAZWT is a control line handled in parallel to PGP1- TAZc.517delG and PGP1-
TAZc.517ins, but without a TAZ mutation. iPSC-CMs derived from these isogenic TAZ
mutant lines fully recapitulated the cardiolipin, mitochondrial, and ATP deficits that we
observed in patient-derived iPSCs and in the neonatal rat TAZ knockdown model (Fig. 3d–
g; Supplementary Table 2). Together, these data indicate that TAZ mutation alone is
sufficient to cause these phenotypes in a wild-type genetic background.
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Mitochondria regulate cardiomyocyte maturation17, a hallmark of which is assembly of
organized arrays of sarcomeres. We noticed that BTH-H iPSC-CMs grown on unpatterned
gelatin substrate assembled sarcomeres irregularly compared to controls. To precisely
compare sarcomere architecture, we engineered iPSC-CM shape by seeding the cells on
micropatterned fibronectin rectangles designed to mimic the dimensions of human adult
cardiomyocytes18, with length:width ratios of approximately 7:1 (95 µm × 13 µm). To
quantify the global regularity of sarcomere arrangement, we developed an unbiased metric
to score images of patterned iPSC-CMs immunostained for the sarcomere protein α-actinin.
This metric, which we named sarcomere organization, is based on the regularity of
sarcomere spacing, as determined from 2-D Fourier spectra of the sarcomere immunostains
(Supplementary Fig. 9a–c and Methods). While sarcomeres in control iPSC-CMs extended
serially along the entire length of the cell, sarcomeres in patient-derived BTH-H iPSC-CMs
were intermittent and sparse (Fig. 4a). Treatment with TAZ modRNA appeared to restore
sarcomere regularity (Fig. 4a). These differences were reflected in the sarcomere
organization metric, which was lower in BTH-H iPSC-CMs compared to control and was
increased by TAZ modRNA treatment (Fig. 4a). Although glucose culture normalized ATP
levels to a comparable degree compared to TAZ modRNA, glucose culture did not rescue
sarcomere formation (Fig. 4a). These defects in sarcomere assembly were recapitulated in
genome edited PGP1-TAZTAZc.517delG and PGP1-TAZc.517ins iPSC-CMs compared to
isogenic PGP1-TAZWT controls (Fig. 4b), confirming the causative role of the BTH-H exon
6 frameshift TAZ mutation. These data suggest that sarcomerogenesis is sensitive to
mitochondrial function independent of whole cell ATP levels.
Interestingly, BTH-C iPSC-CMs exhibited sarcomere organization that was not significantly
different from controls (Fig. 4c). This phenotypic heterogeneity may be due to the specific
BTH-C missense mutation, or it may be due other variables between cell lines. Further use
of genome-edited cell lines will be necessary to better understand genotype-phenotype
relationships in this disease.
Myocardial constructs model the BTHS myopathic phenotype and its
genetic rescue
Because BTHS patients often develop cardiomyopathy, we asked if we could replicate the
contractile pathophysiology of Barth Syndrome in an in vitro model of engineered
myocardium and demonstrate the efficacy of TAZ modRNA treatment on the disease.
Towards this goal, we used our “heart on a chip” assay5,19 to quantitatively measure
contractility of engineered myocardial tissue assembled from BTHS or control iPSC-CMs.
MACS-selected iPSC-CMs were seeded onto thin elastomers micropatterned with
fibronectin lines and supported by glass coverslips20,21. Over a five day culture period, the
iPSC-CMs self-organized into laminar, anisotropic myocardium. Staining for sarcomeric α-
actinin in control iPSC-CM tissues revealed both aligned sarcomeres and fibrous structures
indicative of the relatively immature phenotype of iPSC-CMs (Fig. 5a), similar to previous
observations in immature primary rat cardiac myocytes.22 Engineered BTHS iPSC-CM
tissues continued to exhibit impaired sarcomere assembly compared to controls
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t(Supplementary Fig. 10a). Pre-cut muscular thin film (MTF) tissue constructs were then
peeled from the glass substrate, allowing them to contract and curl away from the plane of
the coverslip (Fig. 5a; Supplementary Movie 2). Movies of contracting MTFs were used to
calculate radii of curvature, from which we calculated the diastolic and peak systolic stresses
using a modification of Stoney’s equation5,20,23. Twitch stress was calculated as the
difference between diastolic and peak systolic stress (Fig. 5a). During electrical field
stimulation, control iPSC-CM MTFs contracted rhythmically at frequencies ranging from 1–
5 Hz (Fig. 5b; Supplementary Fig. 10b; Supplementary Movie 2). Patient-derived, BTH-H
iPSC-CM tissues were significantly weaker over the same stimulation frequency range,
indicating that BTHS engineered myocardial tissue recapitulates the BTHS myopathic
phenotype.
Next we asked if the engineered myocardial tissue constructs effectively model disease
correction. Treatment of BTH-H iPSC-CMs (Fig. 5b, Supplementary Fig. 10, and
Supplementary Movie 2) with TAZ modRNA for five days restored contractile function to
levels comparable to controls, further confirming that this myopathic phenotype was
reversible and due to TAZ mutation.
We assessed the contribution of whole cell ATP to BTHS contractile dysfunction by
culturing engineered iPSC-CM MTF constructs in glucose, which increased BTHS cellular
ATP levels to a level comparable to TAZ modRNA. In contrast to TAZ modRNA rescue,
glucose culture alone did not restore BTH-H iPSC-CM force generation at any tested
stimulation frequency (Fig. 5b, Supplementary Fig. 10b,c, and Supplementary Movie 3).
Although local pools of mitochondrially produced ATP might theoretically be required for
iPSC-CM force generation, such a mechanism is unlikely because inhibition of
mitochondrial ATP production with oligomycin in control iPSC-CMs did not alter their
contractile strength (Supplementary Fig. 11), consistent with their immature and highly
glycolytic properties. Together, these data show that BTH-H iPSC-CMs have a severe defect
in contractility that occurred independent of ATP depletion. This result is consistent with
anectodal data from BTHS patients that show preserved cardiac high energy phosphate
levels in the setting of impaired heart function (e.g., Supplementary Fig. 12), suggesting that
contractile dysfunction in patients can occur despite normal myocardial energy stores.
The findings from patient-derived, BTH-H iPSC-CMs were reproduced in the isogenic,
genome-edited cells. Contractile function of the mock-manipulated PGP1-TAZWT iPSC-CM
myocardial constructs was equivalent to the parental PGP1 cell line, while TAZ disruption
in both PGP1- TAZc.517delG and PGP1- TAZc.517ins caused severe loss of contractile stress
generation (Fig. 5c; Supplementary Fig. 10c; Supplementary Movie 4). Reintroduction of
TAZ by modRNA restored contractility to mutant tissues. Thus, in both patient-derived cells
and cells with an isogenic background, TAZ deficiency induces contractile dysfunction.
BTH-C myocardial tissue constructs also showed poor contractile function, reflected in their
markedly reduced beating activity (Supplementary Movie 2) and severely depressed twitch
stress (Fig. 5d). Systolic stress generation was also reduced significantly in BTH-C
myocardial tissue constructs compared to controls (Fig. 5d). However, their peak systolic
(and diastolic) stresses were substantially higher than their BTH-H counterparts (Fig. 5d vs
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t5b), perhaps reflecting the difference in sarcomere assembly that we observed between these
TAZ genotypes (Fig. 4a vs. 4c).
Together, these results indicate that TAZ mutation is sufficient to cause a myopathic
phenotype in myocardial tissue constructs, and that this phenotype is readily reversible upon
TAZ replacement.
Assessment of potential therapies using BTHS iPSC-CMs
We used BTHS iPSC-CMs to measure the effect of three proposed interventions for Barth
syndrome: bromoenol lactone, an inhibitor of mitochondrial phospholipase A2, which
catabolizes mature cardiolipin24; linoleic acid (LA), an essential unsaturated fatty acid
precursor of mature cardiolipin25; and arginine plus cysteine, amino acids which are
frequently deficient in BTHS patients26. LA and bromoenol lactone partially corrected the
monolysocardiolipin to cardiolipin ratio, while arginine plus cysteine had no effect (Fig. 6a).
Treatment of galactose-cultured BTHS iPSC-CMs with LA or arginine plus cysteine
increased ATP to levels comparable to control or to TAZ modRNA rescue, while bromoenol
lactone had no significant effect (Fig. 6b). LA, but not arginine plus cysteine, also
normalized basal and F1F0 ATP synthase oxygen consumption rate of BTHS iPSC-CMs but
had little effect on maximal mitochondrial respiratory capacity (Fig. 6c; Supplementary Fig.
13). Thus, of the three tested compounds, LA was most effective at correcting the metabolic
phenotype of BTHS iPSC-CMs.
Because LA had a positive effect in each of these metabolic assays, we asked if LA
supplementation would mitigate the sarcomere organization and contractile defects of
BTHS-iPSC-CMs. LA improved sarcomere organization of BTH-H iPSC-CMs (Fig. 6d). No
statistically significant improvement was noted in BTH-C iPSC-CMs, whose sarcomeric
organization was not significantly different from controls. In both BTH-H and BTH-C
myocardial tissue constructs, LA dramatically increased twitch stress to nearly normal levels
(Fig. 6e). This was reflected in the obvious effect of LA on rhythmic beating of the BTHS
myocardial MTF constructs (Supplementary Movie 5). Thus, LA rescued the contractile
deficits of BTHS iPSC-CMs.
In addition to potentially enhancing alternative CL synthesis pathways, LA might also
influence BTHS iPSC-CM phenotype by scavenging reactive oxygen species (ROS).
Extensive literature implicates high levels of ROS in ischemic and hypertensive heart
failure, in part through effects on sarcomere assemby and function.27 Uncoupling of the
electron tranport chain and elevated mitochondrial membrane potential, both observed in
BTHS iPSC-CMs (Fig. 1 and Supplementary Fig. 14a–d), promote mitochondrial ROS
production. Indeed, we found that mitochondrial ROS production was markedly increased in
BTHS iPSC-CMs, as assessed by measurement of 4-hydroxynonenal (4-HNE), a product of
lipid peroxidation, or by Mitosox, a mitochondrially targeted probe with ROS-enhanced
fluorescence (Supplementary Fig. 14e). 4-HNE levels were suppressed to near baseline by
LA (Fig. 6f). To distinguish antioxidant from CL-precursor mechanisms of LA action, we
tested the mitochondrially targeted and structurally unrelated antioxidant mitoTEMPO. Like
LA, mitoTEMPO suppressed excessive ROS in BTHS iPSC-CMs (Fig. 6g).
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BTHS iPSC-CMs, we next determined if mitoTEMPO treatment improved sarcomere
organization and force generation of these disease cardiomyocytes. Indeed, mitoTEMPO
treatment normalized sarcomere organization and contractility of BTHS iPSC-CMs (Fig.
6h–i; Supplementary Movie 6).
These data indicate that iPSC-CMs and heart-on-chip technology enable effective in vitro
testing of candidate therapeutic agents. Furthermore, these data link impaired
sarcomerogenesis and weak force generation in BTHS iPSC-CMs to excessive ROS
production.
Discussion
Patient-derived iPSCs have significant potential to enhance our understanding of human
disease and enable therapeutic screening on a personalized basis. However, several barriers
still hinder adoption of iPSC disease models academically, clinically, and commercially.
One obstacle to wider use of iPSC disease models has been the genetic and epigenetic
variation between cell lines, which introduces confounding variables that can be difficult to
control. We show that Cas9-mediated genome editing is an excellent strategy to isolate a
mutation of interest and show that it is sufficent to cause a disease phenotype. Gene
replacement using modified RNA technology is another highly portable approach that
demonstrates the acute requirement of a gene mutation for a disease phenotype within a
given cell line.
Another major impediment to the use of iPSCs to study human disease pathogenesis has
been the lack of in vitro models that reproduce disease pathophysiology. With respect to
cardiomyopathies, modeling the contractile function of iPSC-CMs at the level of myocardial
tissue has been challenging, and prior iPSC-based models of cardiomyopathy have focused
on measurements of single cell contractile function28,29. Here, we assembled anisotropic,
laminar myocardial tissue constructs from iPSC-CMs and used these to document impaired
contractile stress generation in BTHS. Furthermore, we use this approach to model
phenotypic rescue at the tissue level by gene replacement and small molecule treatments.
Our metabolic and functional analysis of human Barth syndrome cardiomyocytes elucidated
mitochondrial functional impairment caused by mature cardiolipin depletion. Our data show
that the contracile deficit of BTHS iPSC-CMs is not a result of global cellular energy
depletion. Rather, we show that TAZ deficiency in BTHS impairs sarcomere assembly and
contractile stress generation. It is likely that sarcomere assembly is only one of several
factors that lead to reduced twitch stress in BTHS iPSC-CMs, since the extent of sarcomere
disarray did not necessarily correlate with impairment of twitch stress across our assays.
We found that TAZ deficiency in BTHS caused markedly increased ROS production, and
suppression of ROS normalized the metabolic, sarcomerogenesis, and contractile
phenotypes of BTHS iPSC-CMs. These data indicate that excessive ROS production
contributes to sarcomere disarray and reduced contractile stress generation in BTHS iPSC-
CMs. ROS has been implicated in cardiomyocyte differentiation, sarcomerogenesis, and
Wang et al. Page 8
Nat Med. Author manuscript; available in PMC 2014 December 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tcontractility.17,27 Our data indicate that ROS scavenging may be beneficial for BTHS
patients and suggest that this strategy should be further validated using in vivo models. Our
findings may be relevant to more common diseases such as ischemia and aging, since
mature cardiolipin depletion and elevated ROS production also occur in these conditions3.
Online Methods
Cell culture
Low passage skin fibroblasts were obtained from skin biopsies from two unrelated BTHS
patients with informed consent under protocols approved by the Boston Children’s Hospital
Institutional Review Board. WT1 control cells were derived from BJ cells (Stemgent), while
WT2 and WT3 were described previously7,8,30. The BTH-H iPSC line was established by
retroviral delivery of four reprogramming factors (OCT4, SOX2, KLF4 and OCT4)6. The
BTH-C iPSC line was established by modRNA reprogramming as described7. Several iPSC
clones with ES cell morphology and with positive vital staining for TRA-1–81 or TRA-1–60
staining31, were further characterized to yield the final two lines studied. Karyotyping was
performed by Cell Line Genetics, Inc. Teratomas were formed by injection of 106 iPSCs
intramuscularly into the flanks of adult SCID mice under protocols approved by the Boston
Children’s Hospital Institutional Animal Care and Use Committee. Teratomas were
examined by H&E and immunofluorescent staining.
Cardiomyocyte differentiation was induced as previously reported9, with minor
modifications. Cells were detached by 3–5 min incubation with Versene (Invitrogen) and
seeded onto Matrigel-coated plates at a density of 10,000 cells/cm2 in murine embryonic
fibroblast conditioned medium (MEF-CM) plus 4 ng/mL bFGF for 2–3 days before
induction. Cells were covered with matrigel (1:60 dilution) on the day before induction. To
induce cardiac differentiation, we replaced MEF-CM with RPMI+B27 medium
(RPMI-1640, 2 mM L-glutamine, ×1 B27 supplement without insulin) supplemented with
100 ng/mL of Activin A (R&D Systems) for 24 hours, followed by 10 ng/mL human bone
morphogenetic protein 4 (R&D) and 10 ng/mL human basic fibroblast growth factor for 4
days without culture medium changes. The culture medium was subsequently replaced with
RPMI+B27 supplemented with 100 ng/mL of DKK1 (R&D) for 2 days. At day 7, the culture
medium was changed to RPMI+B27 without supplementary cytokines; culture medium was
refreshed every 1–2 days. Leibovitz L-15 medium was substituted for RPMI for galactose
containing culture media.
For iPSC-CM enrichment, differentiation cultures were dissociated with Accumax
(Innovative Cell Technologies). Dissociated cells were stained with anti-VCAM1 antibody
(refer to Supplementary Table 1 for antibody information) conjugated with allophycocyanin
(APC) and magnetically sorted using anti-APC microbeads (Miltenyi Biotec). For validation
of MACS, sorted cells were fixed and stained with TNNT2-Alexa-488. Data were analyzed
with FlowJo (Treestar) software.
NRVMs were isolated from neonatal rat heart ventricles by collagenase digestion using the
Neomyts isolation kit (Cellutron). Procedures involving animals were performed under
protocols approved by the Institutional Animal Care and Use Committee.
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tFor MitoTEMPO treatment, iPSC-CMs were purified by VCAM1 MACS and reseeded on
muscle thin films at 1 million cells per well of a six well plate (see below). The cells were
treated with MitoTEMPO at a final concentration of 5 µM for 5 days.
Cas9 Genome Editing
Details of our modified Cas9 genome editing strategy will be published separately. In brief,
we constructed a piggyBac transposon that expresses the reverse tet activator and a human
codon optimized Cas9 under the control of a tet response element. Transient transfection of
PGP1-iPSCs (Coriell) with piggyBac and this engineered transposon yielded PGP1iPSC-
hCas9. We subsequently designed guide RNA and donor oligonucleotides (Fig. 3a–c;
Supplementary Fig. 8; and Suppl. Table 4) to introduce the BTHH TAZ mutation into exon
6. After transient dox administration and transfection with gRNA and donor
oligonucleotides, we screened individual clones by Sanger sequencing. We selected an
unmodified clone, a clone containing the BTHH mutation (homologous recombination), and
a clone containing a novel insertion due to non-homologous end joining. Transient piggyBac
transfection subsequently led to removal of the Cas9-containing transposon.
TAZ sequencing
TAZ sequencing was performed using previously described primers32, listed in
Supplementary Table 4. Mutations are referenced to Refseq NM_000116.3.
Cardiac 31P-NMR
Cardiac 31P-NMR was performed as described33with informed consent under a protocol
approved by the Institutional Review Board of the Children’s Hospital of Philadelphia. High
energy phosphate stores were estimated from the phosphocreatine peak area, normalized to
the peak area from the β-phosphate of ATP33.
Mitochondrial Function Assays
For mitochondrial function assays, 60,000 sorted cells were seeded in 0.1% gelatin-coated
seahorse assay wells in alpha MEM (Invitrogen) with 10% FBS. They were then changed to
L-15 media supplemented with 1× B27 supplement without insulin for 5–7 days. Oygen
consumption rate (OCR) was measured using a Seahorses Biosciences XF24 extracellular
flux analyzer and normalized to total protein, determined using the BCA protein assay
(Thermo Scientific). OCR was expressed as pmol/min/10 µg protein. For ATP assays, cells
were grown in indicated media and supplements for 5 days. ATP assay reagent (Promega)
was added directly to wells and light output was measured with a plate luminometer.
Readout was normalized to total protein.
Mitochondrial Isolation and FACS Analysis
Mitochondrial isolation and FACS analysis were performed to measure mitochondrial size,
number, membrane potential, and production of reactive oxygen species. Mitochondrial
isolation and FACS were performed based on described protocols.28studying its in vivo
relevance to angiogenesis.his mechanistic hypothesis is being specifically tested by Dr.
Zhang. He is al34 In brief, iPSC-CMs were digested to single cells by Versene and
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millions iPSC-CMs were pelleted by centrifugation at 850g for 2 minutes. The pellet was
resuspended in 800 µl of mitochondria isolation reagent A with protease inhibitor. The
suspension was vortexed at medium speed for 5 seconds and then incubated on ice for
exactly 2 minutes. Then 10 µl mitochondria isolation reagent B was added and vortexed at
maximum speed for 5 seconds. After 5 minutes incubation on ice with vortexing at
maximum speed every minute, 800 µl mitochondria isolation reagent C with protease
inhibitor was added. The tube was centrifuged at 700g for 10 minutes at 4°C. The
supernatant was transferred to a new microfuge tube and centrifuged at 3000g for 15
minutes. The supernatant was discarded and 500 µl mitochondria isolation reagent C was
added to the pellet. The sample was then centrifuged at 12000g for 5 minutes. The
mitochondria pellet was resuspended in 200 µl FACS buffer (Stemcell Technologies Inc).
Either MitoSox (5 µM) or TMRM (100 nM) and Mitotracker Green (50 nM) were incubated
with mitochondria for at room temperature for 30 minutes. The sample was then analyzed by
flow cytometry. Data were analyzed by using Flowjo software.
shRNA adenovirus
Control and TAZ shRNA viruses were constructed as described previously35 using
sequences provided in Supplementary Table 4.
Imaging and Gene expression analysis
Immunostaining for marker expression was performed using antibodies listed in
Supplementary Table 3. Samples were fixed in 4% paraformaldehyde and permeabilized
with 0.05% Triton X-100. Imaging was performed on an Olympus FV1000 or Zeiss LSM 5
LIVE confocal microscope. qRTPCR was performed from total RNA using primers listed in
Supplementary Table 4. Sybr green chemistry was used for real time PCR detection on an
ABI 7500 instrument.
Mitochondria were labeled using BacMam 2.0 mitochondria-RFP (Invitrogen), in which
baculovirus delivers RFP tagged with the mitochondrial localization sequence of E1 alpha
pyruvate dehydrogenase.
Electron microscopy was performed on a Tecnai G Spirit BioTWIN instrument. At least 10
randomly selected fields containing cardiomyocytes were imaged per sample.
Modified RNA synthesis and delivery
The iPSC reprogramming cDNA templates were obtained from Addgene7. The TAZ
modRNA cDNA template was expressed from pcDNA3.3-TOPO-T7–5’UTR-cMyc-3’UTR,
which contains the T7 promoter and optimized 5’ and 3’ untranslated regions (Addgene
plasmid 26818)7. The vector was modified to place unique AscI and NheI restriction sites
between the 5’ and 3’ untranslated regions. Full length human TAZ cDNA corresponding to
Refseq NM_000116 with a 5’ FLAG tag was cloned into modified vector.
To synthesize the modRNA, the UTRs and ORF were PCR amplified using a polyA-tailed
primer. 1.6 µg of purified PCR productwas transcribed in a 40 µl reaction system using the
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tMEGAscript T7 kit (Ambion, Austin, TX) and a custom ribonucleoside cocktail from Allele
Biotechnology (No. ABP-PP-NTPMIX), containing pseudouridine-5′-triphosphate,
Methylcytidine-5′-triphosphate, GTP, ATP, and ARCA (Cap Analog). Reactions were
incubated 6 hr at 37°C. After DNase treatment RNA was purified with Ambion MEGAclear
spin columns, then treated with Antarctic Phosphatase (New England Biolabs) for 30 min at
37°C. Treated RNA was repurified and adjusted to 100 ng/mL working concentration with
Tris-EDTA (pH 7.0).
Modified mRNA transfection were performed with RNAiMAX (Invitrogen). Transfection
media was supplemented with 200 ng/ml B18R interferon inhibitor (eBioscience). After 4
hours, the transfection medium was replaced with fresh culture medium containing 200
ng/ml B18R.
Microcontact Printing
Standard soft lithography techniques were used to fabricate polydimethylsiloxane (PDMS)
stamps for microcontact printing (Sylgard 184, Dow Corning Midland, MI), as previously
described36,37. Briefly, a silicon wafer was spun coat with SU-8 3005 (MicroChem Corp.,
Newton, MA) and selectively exposed to UV light using a photomask. After being
developed, the wafer was used as a template for PDMS stamps. For the single cell studies,
we used stamps with 95 µm ×13 µm rectangles. For the muscular thin film studies, we used
stamps with 15 µm wide lines separated by 2 µm.
To measure sarcomere organization in single cell studies, glass coverslips (diameter 18 mm)
were spun coat with PDMS and cured. PDMS stamps were coated with 50 µg/mL
fibronectin (BD Biosciences, San Jose, CA) for one hour, dried, and inverted onto the
coverslips after treatment in a UVO cleaner (Jelight Company Inc., Irvine, CA). Stamps
were removed and the coverslips were incubated in 1% F127 Pluronic Acid (BASF, Mount
Olive, NJ) for at least five minutes before rinsing with PBS and storage at 4°C. MACS-
purified iPSC-CMs were plated on microfabricated fibronectin islands for five days and
transfected daily with the indicated modRNA.
Quantitation of Sarcomere Organization
For quantitation of sarcomere organization of iPSC-CM plated on fibronectin islands,
images of single myocytes stained for sarcomeric α-actinin were analyzed using custom-
designed software in ImageJ (NIH, Bethesda, MD) and MATLAB (Mathworks, Natick,
MA). Images were pre-processed to highlight the filamentous structure of the cytoskeleton
using a tubeness operator38, which replaces each pixel in the image with the largest non-
positive eigenvalue of the image Hessian matrix. To calculate the ability of single cells to
spread across the microcontact printed islands, the convex hulls39 of sarcomeric α-actinin
and fibronectin binarized immunostains were obtained and utilized to calculate cell
projected surface area.
The regularity of spacing between the cytoskeletal elements that stained positive for
sarcomeric α-actinin (Supplementary Fig. 9 Ai and Bi) was assessed by first considering the
magnitude of the oscillatory portion of the 2D Fourier transform of pre-processed and
binarized immunostains (Supplementary Fig. 9 Aii and Bii):
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To fully automate the analysis and remove any user-bias40, 512 radial profiles of the 2D
Fourier transform were summed to obtain a 1D representation – Γ(ωn) – of the 2D spectrum
(blue-dots in Supplementary Fig. 9 Aiii and Biii) that was further normalized so that the
total area under the curve would be 1. A least square minimization was performed to find the
vector of parameters γ for which the function Γ̃(ω,λ) best fit the N experimental data points:
(2)
(3)
The functional form of Γ(ω,λ) was composed by an aperiodic component, representing the
effect of poorly developed cytoskeletal structures (black curve, Equation (4)) and a periodic
component (red curves, Equation (5)) relating to periodically spaced Z-disks:
(4)
(5)
In agreement with Fourier analysis, the periodic component was approximated with a series
of Gaussian peaks localized at integer multiples of the spatial frequency (ω0 =1/r0)
associated with the sarcomere length (r0 ~ 2 µm).
The area under the peaks of the periodic component was taken as a metric of structural
organization and named sarcomere organization: that is, the organization increases as more
sarcomeric α-actinin positive elements become localized in the Z-disks, at a distance ~r0.
We normalized all sarcomere organization values to the maximum value observed across all
single cells before plotting.
Muscular Thin Film Fabrication and Experiments
Muscular thin film (MTF) chips were fabricated on 22 mm × 22 mm × 0.13–0.16 mm thick
glass coverslips (Ted Pella Inc., Redding, CA).19,20 Coverslips were covered with low
adhesion Scotch tape (3M, St. Paul, MN) and two rectangles of dimensions 18 mm × 5.8
mm spaced 8.6 mm apart (center to center distance) were cut into the tape with a 10.6
micron wavelength CO2 laser prototyping system (VersaLaser 2.0, 10W, Universal Laser
systems, Scottsdale, AZ). Cut rectangles were peeled using a sharp tweezer and then 10%
(w/v) solution of poly(N-isopropylacrylamide), PIPAAm, (Polysciences, Inc., Warrington,
PA) in 99% butanol was spun coat at 6000 rpm for 1 minute. This allowed the PIPAAm
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tdeposition within bare glass regions. The rest of the tape was then peeled off and PDMS
mixed at 10:1 base to curing agent ratio was spun coat at 4000 rpm for 1 minute. PDMS-
coated chips were placed in a 65°C for at least 8 hours to allow complete curing of the
elastomer. Young's modulus in compression of the cured Sylgard 184 mixed in the ratio of
10:1 base to curing agent ratio was determined to be 1.52 ± 0.05 MPa (N = 18 samples,
Mean ± Standard deviation) using an Instron 3342 mechanical apparatus (Instron, Norwick,
MA). In the final step, two rows of cantilever outlines were cut into the elastomer within the
PIPAAm rectangular regions such that the final cantilevers were 5 mm × 2 mm, or 3 mm ×
2mm,spaced 2.5 mm apart (center to center distance).19 For each batch of films, the
thickness of the elastomer was measured using a profilometer (Dektak 6M, Veeco
Instruments Inc., Plainview, NY) and found to be in the range of 11.4–13.4 µm.
MACS-purified iPSC-CMs were seeded on MTF constructs at a density of 105/cm2 and
allowed to develop for five days, with daily transfection with modRNA as indicated. For
contraction assays, MTF constructs were transferred to 37°C Tyorde’s buffer solution (1.8
mM CaCl2, 5 mM HEPES, 1 mM MgCl2, 5.4 mM KCl, 135 mM NaCl, 0.33 mM NaH2PO4,
and either 5 mM glucose or galactose depending on the experimental conditions, pH 7.4)
and placed on the stage of a Zeiss Discovery V8 Stereo Microscope at room temperature.
Tweezers were used to manually peel each thin film away from the glass coverslip as the
PIPAAm layer dissolved due to the slight drop in temperature. When all films were peeled,
the constructs were re-warmed to 37°C and paced with platinum field stimulation electrodes.
Films were paced at 1, 2, 3, 4, and 5 Hz and their movement was recorded from above at
100 frames per second. Films paced at 2 Hz were used for statistical comparison because
this frequency was closest to the spontaneous beat rate.
MTF stress quantitation
The longitudinal planar projections of contracting MTFs were automatically detected using
custom ImageJ (NIH, Bethesda, MD) software and used to calculate the radius of curvature
of each film using custom MATLAB (Mathworks, Natick, MA) software, as previously
described.5 The stress of the cell layer was determined from the radius of curvature using a
modified form of Stoney’s equation:
(6)
where σcell is the stress of the cell layer, E, v and ts are the Young’s modulus, Poisson’s
ratio, and thickness of the PDMS film, respectively, R is MTF radius of curvature, and tc is
cell layer thickness. Equation (6) can be readily derived based on the theory of the
cylindrical bending of thin plates41 and the static equilibrium of the force and torque of plate
bending42. Note that the plate modulus E/(1 − v2) instead of the biaxial modulus E/(1 − v),
appears in equation (6) because the anisotropic contraction of the cell layer bends the PDMS
film into a cylindrical shape instead of a bowl-like shape. The factor (1 + tc/ts)−1 is a
correction to the standard Stoney’s equation42 when the thickness of the cell layer
approaches that of the PDMS layer. We previously used a more comprehensive model23 to
calculate not only the stress in the film but also the shortening of the muscle layer. For the
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so we chose to adopt the simpler analytical form of the modified Stoney’s equation.
Stress values failed the Shapiro-Wilkinson test for normality and were thus statistically
compared using Kruskal-Wallis One-Way ANOVA on Ranks and Dunn’s method for
pairwise comparisons. Tests with a p-value less than 0.05 were considered statistically
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFig. 1. Mitochondrial abnormalities in BTHS iCMs
a. Mass spectrum of control and BTH-H phospholipids showing mature cardiolipin (CL) and
immature cardiolipin (monolysocardiolipin; MLCL) content of BTHS vs control iPSC-CMs.
b. Comparison of MLCL/CL ratio in BTH-H, BTH-C, and control iPSC-CMs. The dashed
line indicates the clinical diagnostic threshold for BTHS.
c. ATP levels in BTHS and control iPSC-CMs cultured in galactose. n=3. NS, not
significant.
d–e. Assessment of BTH-H and control iPSC-CM mitochondrial function in galactose
culture. Function was measured using cellular oxygen consumption rate (OCR), normalized
to total protein. Oligo, oligomycin. FCCP, carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone. A/R, antimycin plus rotenone. Measures of
mitochondrial function (defined in Supplementary Fig. 5b,c) were quantitatively compared
between control and BTH-H iCMs. n=3. *, P<0.05.
f. ATP levels in BTHS and control iPSC-CMs cultured in glucose. n=3.
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tFig. 2. TAZ deficiency is necessary to cause the iPSC-CM metabolic phenotype
a. Subcellular localization of FLAG-tagged TAZ, delivered to iPSC-CMs by modified RNA
(modRNA) transfection. Localization to mitochondria was assessed by co-localization with
virally delivered RFP targeted to mitochondria. FLAG co-localized with RFP. Bar = 10 µm.
b. TAZ modRNA restored cardiolipin biogenesis. BTH-H or control iPSC-CMs were
transfected with the indicated modRNA and cardiolipin composition was measured by mass
spectroscopy. MLCL/CL below 0.3 (dotted line) is considered normal.
c. Effect of TAZ modRNA on mitochondrial function in control and BTHS iPSC-CMs.
Mitochondrial function was measured by extracellular flux analysis as detailed in
Supplementary Fig. 5b,c.
d. Quantitation of mitochondrial functional parameters from c. n=3.
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te. F1F0 ATP synthase specific activity, measured by selective complex immunocapture.
n=6.
*, P<0.05 compared to each other group.
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tFig. 3. Construction and characterization of TAZ mutant and isogenic control iPSCs by Cas9-
mediated genome editing
a. Schematic of genome editing strategy.
b. Strategy for modification of TAZ exon 6 using Cas9, the indicated guide RNA (gRNA),
and the indicated repair oligo.
c. Sequence of a region of TAZ exon 6 in selected genome-edited cell lines. Purple boxes
indicate deletion (Δ) or insertion. PGP1-TAZWT was handled in parallel but was not
modified and had wild-type TAZ sequence.
d. Cardiolipin maturation in TAZ and isogenic control iPSC-CMs, as determined by
phospholipid mass spectroscopy.
e. Basal ATP level of TAZ mutant and isogenic control iPSC-CMs cultured in galactose
media. **, p<0.01. n=3.
f. F1F0 ATPase specific activity, measured from selectively immunocaptured proteins, in
TAZ mutant and isogenic control iPSC-CMs. **, p<0.01. n=3.
g. Abnormalities of mitochondrial function in TAZ mutant iPSC-CMs, as measured by
extracellular flux mitochondrial function assay. iPSC-CMs were transfected with the
indicated modified RNA for 5 days. **, p<0.01 by 1-way ANOVA with Dunnett’s post-hoc
test compared to PGP1-TAZWT+nGFP. n=3.
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tFigure 4. Impaired sarcomere organization in BTHH mutant iPSC-CMs
iPSC-CMs were seeded on micropatterned fibronectin rectangles with length:width ratios of
7:1 (95 µm × 13 µm), fixed, and stained for α-actinin. Sarcomere organization was
quantitated by an unbiased 2D Fourier transform-based algorithm (see Supplemental
Methods). Bar = 10 µm.
a. Sarcomere organization of patient-derived BTH-H and control iPSC-CMs. Sarcomere
organization was tested in the indicated culture medium and after transfection with the
indicated modified RNA. P < 0.05 vs: *, BTH-H + nGFP, gal; #, BTH-H + nGFP, glu.
b. Sarcomere organization of genome-edited, isogenic PGP1 iPSC-CMs containing the
indicated TAZ variant. iPSC-CMs were transfected with the indicated modified RNA. P <
0.05 vs: *, PGP1-TAZ-517delG + nGFP; #, PGP1-TAZ-517ins.
c. Sarcomere organization of patient-derived BTH-C and control iPSC-CMs.
Statistical comparisons were made by ANOVA with Fisher LSD post-hoc test. NS, not
significant. Sample number is displayed within each bar.
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tFigure 5. Depressed contractile stress generation by BTHS myocardial tissue constructs
a. iPSC-CMs seeded onto thin elastomers with patterned lines of fibronectin self-organized
into anisotropic myocardial tissues referred to muscular thin films (MTFs). Cardiomyocyte
stress generation reduces the radius of curvature of the construct as it contracts from diastole
to peak systole. Red lines indicate automated MTF tracking projected onto the horizontal
plane. Blue lines indicate lengths of MTFs prior to peeling from substrate. Bar, 100 µm.
b–d. Twitch stress and peak systolic stress generated by MTFs from patient-derived BTH-H
and control iPSC-CMs (b), genome-edited TAZ frameshift and control iPSC-CMs (c), and
patient-derived BTH-C and control iPSCs (d) at 2 Hz pacing. (b) P<0.05 vs: *, BTHH
+nGFP, gal; #, BTH-H+nGFP+glu. (c) P<0.05 vs: *, PGP1-TAZc.517delG+nGFP; #, PGP1-
TAZc.517ins+nGFP. (d) *, P<0.05 vs: BTH-C+nGFP.
Statistical comparisons were made by Kruskal-Wallis One Way ANOVA on ranks and
Dunn’s post-hoc test. Sample size is indicated by number inside each bar.
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tFig. 6. Effect of small molecules on BTHS iCM ATP levels and mitochondrial function
a–c. BTHS iCMs were treated with linoleic acid (LA), bromoenol lactone (BEL), or
arginine plus cysteine (A/C) for 5 days in galactose-containing media, and the effect on
cardiolipin maturation (a), cellular ATP levels (b, n=3), and mitochondrial function (c, n=3)
were measured. *, P<0.05 vs. control. V, vehicle.
d. Effect of LA treatment on sarcomeric organization compared to vehicle (V). LA increased
BTHH sarcomeric organization but did not have a significant effect on BTHC sarcomeres.
One-way ANOVA. P < 0.05 vs: *, BTHH + V; #, BTHC + V.
Wang et al. Page 24
Nat Med. Author manuscript; available in PMC 2014 December 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
te. Effect of LA treatment on muscular thin film contractile stress generation. Twitch strength
of BTHH and BTHC constructs were dramatically enhanced by LA treatment compared to
vehicle (V). Kruskal-Wallis with Dunn’s post-hoc test. Numbers inside bars indicate sample
size. P < 0.05 vs: *, BTHH + V; #, BTHC + V
f. Lipid peroxidation in BTHS and control iPSC-CMs. Cells were cultured in glucose and
treated with LA and the indicated modRNA for 5 days. The lipid peroxidation product 4-
hydroxynonenal was measured by ELISA. One-way ANOVA. n=6. *, P<0.05 vs *, WT1 +
nGFP; #, BTHH + nGFP.
g. Mitochondrial ROS in BTHS and control iPSC-CMs and its suppression by MitoTEMPO.
Cells were treated with MitoTEMPO (MT) or vehicle (V). Mitochondrial ROS was assessed
by FACS measurement of Mitosox fluorescence of isolated mitochondria. Representative
histograms are shown to the right, with dotted line indicating the peak MitoSox signal
intensity from WT1+V. One-way ANOVA. n=3. P<0.05 vs *, BTHH + V; †, PGP1-
TAZc.517delG + V.
h. Effect of MitoTEMPO on sarcomeric organization of iPSC-CMs plated on fibronectin
rectangles. Numbers inside bars indicate cells analyzed. One-way ANOVA. P<0.05 vs *,
BTHH + V; †, PGP1-TAZc.517delG + V.
i. Effect of MitoTEMPO on force generation by iPSC-CM myocardial tissue constructs.
Numbers inside bars indicate thin films analyzed. Kruskal-Wallis with Dunn’s post-hoc test.
P<0.05 vs *, BTHH + V; †, PGP1-TAZc.517delG + V.
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